MIRA PHARMACEUTICALS, INC. - 8-K Filing
Mira Pharmaceuticals secured worldwide exclusive rights to its drug candidates MIRA-55 and SKNY-1 through an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, effective June 3, 2026. The agreement grants the company global development, commercialization, sublicensing, and IP enforcement rights for both programs without materially altering prior economic terms. (Items: 1.01 Entry into a Material Definitive Agreement, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $MIRA